AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 12 min read$PHVS

Lesage Anne sold $1.4M of PHVS

Lesage Anne (Chief Early Development) sold 38,472 shares of Pharvaris N.V. (PHVS) at an average of $35.37 ($35.05–$35.48, $1.36M total) across 3 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lesage Anne
Published Jul 1, 2026, 11:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider liquidity and potential sentiment, but it does not introduce new operational or financial information about PHVS.

02

Market read

A $1.36M planned insider sale is unlikely to be a standalone driver, but it can slightly influence short-term sentiment and positioning.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent news catalysts (none provided here) or unusual follow-on selling beyond planned schedules.

Relevance 5/10Novelty 4/10Timing: Filed July 1, covering sales dated June 29–30

Background

This is an SEC Form 4 insider transaction for Pharvaris N.V. (PHVS), reported by Chief Early Development Lesage Anne.

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

Insider Lesage Anne (Chief Early Development) sold $1.36M of PHVS shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 showing a planned sale window and weighted-average prices, but it does not include new company performance, guidance, or regulatory/clinical developments.

Market effects

Sector

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying fundamentals.

Regional

None indicated; single-company Form 4 filing.

Global

None indicated; no cross-border deal/regulatory event described.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    PHVS

    Pharvaris N.V., the company whose shares were sold by an insider.

  • insider
    Lesage Anne

    Chief Early Development who executed open-market sales under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min